Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia (FINLEVO)

University of Helsinki

Status: Completed

Conditions: Bacteremia; Endocarditis; Staphylococcus Aureus; Sepsis

Treatments: Drug: trovafloxacin and levofloxacin

Study type: Observational

Funder types: Other

Identifiers

NCT00548002

210275

Details and patient eligibility

About

To study whether fluoroquinolone (trovafloxacin or levofloxacin), added to standard treatment, could reduce the high mortality and complication rates in Staphylococcus aureus bacteremia.

Enrollment: 430 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Adult patients with at least 1 blood culture positive for Staphylococcus aureus were included within 1 to 7 days of blood culture sampling.

Exclusion criteria

• age younger than 18 years
• imprisonment
• proven or suspected pregnancy
• breastfeeding, epilepsy
• another bacteremia during the previous 28 days
• polymicrobial bacteremia (_>3 microbes)
• history of allergy to any quinolone antibiotic
• previous tendinitis during fluoroquinolone therapy
• prior fluoroquinolone use for more than 5 days before randomization
• positive culture for Staphylococcus aureus only from a central intravenous catheter
• neutropenia (<0.5 x 109/L) or failure to supply an informed consent
• patients with bacteremia due to methicillin-resistant S. aureus and a S. aureus strain resistant to any fluoroquinolone
• patients with meningitis at the time of randomization

Trial design

430 participants in 1 patient group

1 and 2

Description:

Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).

Treatment:

Drug: trovafloxacin and levofloxacin